In a recent legal turn of events, biochemical startup Liquidia has been given approval to launch its drug for lung disease. The clearance was given by a federal judge from Delaware, which swiftly followed the Federal Circuit’s decision to uphold a patent board ruling.
This move by the Federal Circuit effectively discontinued the remaining claims on a hypertension patent owned by United Therapeutics. United Therapeutics’ patent had previously been a hurdle for Liquidia, hindering the launch of its drug in the market.
Now, with the claims in the hypertension patent removed, Liquidia is free to move forward with its lung disease drug. This ruling may have significant implications for both companies and could act as a precedent for similar future cases involving patent disputes within the pharmaceutical industry.
For a more comprehensive look at this development, legal professionals can refer to the detailed coverage of this case on Law360.